By Professor David Goldstein

Journal articles

Butow P; Müller F; Napier CE; Bartley N; Ballinger ML; Biesecker B; Juraskova I; Meiser B; Schlub TE; Thomas DM; Goldstein D; Best MC; Newson A; Tucker K; Vines R; Vines K; Kirk J; Young MA; Savard J; Jacobs C, 2021, 'Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling', Psycho-Oncology, 30, pp. 1920 - 1929, http://dx.doi.org/10.1002/pon.5764

Thavaneswaran S; Ballinger M; Butow P; Meiser B; Goldstein D; Lin F; Napier C; Thomas D; Best M, 2021, 'The experiences and needs of australian medical oncologists in integrating comprehensive genomic profiling into clinical care: A nation-wide survey', Oncotarget, 12, pp. 2169 - 2176, http://dx.doi.org/10.18632/ONCOTARGET.28076

Maharaj AD; Evans SM; Zalcberg JR; Ioannou LJ; Graco M; Croagh D; Pilgrim CHC; Dodson T; Goldstein D; Philip J; Kench JG; Merrett ND; Neale RE; White K; Evans P; Leong T, 2021, 'Barriers and enablers to the implementation of multidisciplinary team meetings: A qualitative study using the theoretical domains framework', BMJ Quality and Safety, 30, pp. 792 - 803, http://dx.doi.org/10.1136/bmjqs-2020-011793

Li T; Mizrahi D; Goldstein D; Kiernan MC; Park SB, 2021, 'Chemotherapy and peripheral neuropathy', Neurological Sciences, 42, pp. 4109 - 4121, http://dx.doi.org/10.1007/s10072-021-05576-6

Clifford BK; Jones MD; Simar D; Barry BK; Goldstein D, 2021, 'The effect of exercise intensity on exercise-induced hypoalgesia in cancer survivors: A randomized crossover trial', Physiological Reports, 9, pp. e15047, http://dx.doi.org/10.14814/phy2.15047

Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB, 2021, 'Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy', Gait and Posture, 89, pp. 178 - 185, http://dx.doi.org/10.1016/j.gaitpost.2021.07.010

Lees JG; Abdulla M; Barkl-Luke ME; Livni L; Keating BA; Hayes J; Fiore NT; Park SB; Moalem-Taylor G; Goldstein D, 2021, 'Effect of exercise on neuromuscular toxicity in oxaliplatin-treated mice', Muscle and Nerve, 64, pp. 225 - 234, http://dx.doi.org/10.1002/mus.27329

Giraud P; Racadot S; Vernerey D; Goldstein D; Glimelius B; Van Houtte P; Gubanski M; Spry N; Van Laethem JL; Hammel P; Huguet F, 2021, 'Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma', International Journal of Radiation Oncology Biology Physics, 110, pp. 993 - 1002, http://dx.doi.org/10.1016/j.ijrobp.2021.01.055

Schernberg A; Vernerey D; Goldstein D; Van Laethem JL; Glimelius B; van Houtte P; Bonnetain F; Louvet C; Hammel P; Huguet F, 2021, 'Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma', International Journal of Radiation Oncology Biology Physics, 110, pp. 1022 - 1031, http://dx.doi.org/10.1016/j.ijrobp.2021.01.052

Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA, 2021, 'Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to slc7a11 inhibition', Cancer Research, 81, pp. 3461 - 3479, http://dx.doi.org/10.1158/0008-5472.CAN-20-2496

Battaglini E; Goldstein D; Grimison P; McCullough S; Mendoza-Jones P; Park SB, 2021, 'Chemotherapy-induced peripheral neurotoxicity in cancer survivors: Predictors of long-term patient outcomes', JNCCN Journal of the National Comprehensive Cancer Network, 19, pp. 821 - 828, http://dx.doi.org/10.6004/jnccn.2021.7026

Chiang JCB; Goldstein D; Park SB; Krishnan AV; Markoulli M, 2021, 'Corneal nerve changes following treatment with neurotoxic anticancer drugs', Ocular Surface, 21, pp. 221 - 237, http://dx.doi.org/10.1016/j.jtos.2021.06.007

Taggart J; Chin M; Liauw W; Goldstein D; Dolezal A; Plahn J; Harris MF, 2021, 'Challenges and solutions to sharing a cancer follow-up e-care plan between a cancer service and general practice', Public Health Research and Practice, 31, http://dx.doi.org/10.17061/PHRP31122108

Pang TCY; Xu Z; Mekapogu AR; Pothula S; Becker T; Corley S; Wilkins MR; Goldstein D; Pirola R; Wilson J; Apte M, 2021, 'Hgf/c-met inhibition as adjuvant therapy improves outcomes in an orthotopic mouse model of pancreatic cancer', Cancers, 13, pp. 2763, http://dx.doi.org/10.3390/cancers13112763

Oar A; Kneebone A; Lee M; Goldstein D; Sjoquist KM; Le H; Chu J; Barbour A; Gholamrezaei L; Lynam JF; Bece A; Bahamad S; Yip S; Espinoza D; Chantrill LA; Moore A; Lee D; Nguyen QN; Samra J; Mumford J, 2021, 'Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.TPS4172

Kokkinos J; Jensen A; Sharbeen G; McCarroll JA; Goldstein D; Haghighi KS; Phillips PA, 2021, 'Does the microenvironment hold the hidden key for functional precision medicine in pancreatic cancer?', Cancers, 13, http://dx.doi.org/10.3390/cancers13102427

Smit AK; Bartley N; Best MC; Napier CE; Butow P; Newson AJ; Tucker K; Ballinger ML; Thomas DM; Jacobs C; Meiser B; Goldstein D; Savard J; Juraskova I, 2021, 'Family communication about genomic sequencing: A qualitative study with cancer patients and relatives', Patient Education and Counseling, 104, pp. 944 - 952, http://dx.doi.org/10.1016/j.pec.2020.10.022

Timmins HC; Li T; Trinh T; Kiernan MC; Harrison M; Boyle F; Friedlander M; Goldstein D; Park SB, 2021, 'Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response', Oncologist, 26, pp. 366 - 374, http://dx.doi.org/10.1002/onco.13697

Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Penel N; Hartmann JT; Duffaud F; Goldstein D; Martin-Broto J; Gronchi A; Wardelmann E; Marréaud S; Zalcberg JR; Litière S; Blay JY, 2021, 'Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)^☆', Annals of Oncology, 32, pp. 533 - 541, http://dx.doi.org/10.1016/j.annonc.2021.01.004

Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D, 2021, 'Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy', JAMA Network Open, 4, pp. E2036695, http://dx.doi.org/10.1001/jamanetworkopen.2020.36695

Trinh T; Park SB; Murray J; Pickering H; Lin CSY; Martin A; Friedlander M; Kiernan MC; Goldstein D; Krishnan AV, 2021, 'Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial', Supportive Care in Cancer, 29, pp. 1103 - 1110, http://dx.doi.org/10.1007/s00520-020-05591-x

Blinman P; Martin A; Jefford M; Goldstein D; Boadle D; Morris M; Tebbutt N; Aiken C; Harkin A; Segelov E; Haydon A; Iveson T; Stockler MR, 2021, 'Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer', JNCI CANCER SPECTRUM, 5, http://dx.doi.org/10.1093/jncics/pkaa107

McNamara MG; Bridgewater JA; Goyal L; Goldstein D; Shroff RT; Moehler MH; Lowery MA; Bekaii-Saab TS; Kelley RK; Furuse J; Rimassa L; Morizane C; Lamarca A; Hubner R; Knox JJ; Valle JW, 2021, 'Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).', Journal of Clinical Oncology, 39, pp. 348 - 348, http://dx.doi.org/10.1200/jco.2021.39.3_suppl.348

Chiang JCB; Goldstein D; Trinh T; Au K; Mizrahi D; Muhlmann M; Crowe P; O’neill S; Edwards K; Park SB; Krishnan AV; Markoulli M, 2021, 'A cross-sectional study of sub-basal corneal nerve reduction following neurotoxic chemotherapy', Translational Vision Science and Technology, 10, pp. 1 - 11, http://dx.doi.org/10.1167/tvst.10.1.24

Pang TCY; Po JW; Becker TM; Goldstein D; Pirola RC; Wilson JS; Apte MV, 2021, 'Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications', Pancreatology, 21, pp. 103 - 114, http://dx.doi.org/10.1016/j.pan.2020.11.022

Cameron B; Webber K; Li H; Bennett BK; Boyle F; de Souza P; Wilcken N; Lynch J; Friedlander M; Goldstein D; Lloyd AR, 2021, 'Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study', Brain, Behavior, and Immunity - Health, 10, pp. 100189, http://dx.doi.org/10.1016/j.bbih.2020.100189

Quinn CM; Porwal M; Meagher NS; Hettiaratchi A; Power C; Jonnaggadala J; McCullough S; Macmillan S; Tang K; Liauw W; Goldstein D; Zeps N; Crowe PJ; Jonnagaddala J, 2021, 'Moving with the Times: The Health Science Alliance (HSA) Biobank, Pathway to Sustainability', Biomarker Insights, 16, pp. 1 - 10, http://dx.doi.org/10.1177/11772719211005745

Tempero M; O'Reilly E; Van Cutsem E; Berlin J; Philip P; Goldstein D; Tabernero J; Borad M; Bachet J; Parner V; Tebbutt N; Chua Y; Corrie P; Harris M; Taieb J; Burge M; Kunzmann V; Zhang G; McGovern D; Marks H; Biankin A; Reni M, 2021, 'LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival', Annals of Oncology, 32, pp. S226 - S226, http://dx.doi.org/10.1016/j.annonc.2021.06.009

Kokkinos J; Ignacio RM; Haghighi K; Kopecky C; Sharbeen G; Gonzales-Aloy E; Youkhana J; Butler L; Goldstein D; McCarroll J; Phillips P, 2021, 'Patient-derived pancreatic tumours in a dish: implications for real-time precision medicine', HPB, 23, pp. S235 - S235, http://dx.doi.org/10.1016/j.hpb.2020.11.590

Maharaj AD; Evans SM; Zalcberg JR; Ioannou LJ; Graco M; Croagh D; Pilgrim CHC; Dodson T; Goldstein D; Philip J; Kench JG; Merrett ND; Neale RE; White K; Evans P; Leong T; Green SE, 2020, 'Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework', PLoS ONE, 15, http://dx.doi.org/10.1371/journal.pone.0243312

Pothula SP; Xu Z; Goldstein D; Pirola RC; Wilson JS; Apte MV, 2020, 'Targeting hgf/c-met axis in pancreatic cancer', International Journal of Molecular Sciences, 21, pp. 1 - 18, http://dx.doi.org/10.3390/ijms21239170

McNamara MG; Lopes A; Wasan H; Malka D; Goldstein D; Shannon J; Okusaka T; Knox JJ; Wagner AD; André T; Cunningham D; Moehler M; Jensen LH; Koeberle D; Bekaii-Saab T; Bridgewater J; Valle JW, 2020, 'Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer', Journal of Hepatology, 73, pp. 1109 - 1117, http://dx.doi.org/10.1016/j.jhep.2020.05.014

Xu Z; Pothula S; Goldstein D; Pirola RC; Wilson JS; Apte MV, 2020, 'Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis', British Journal of Cancer, 123, pp. 1466, http://dx.doi.org/10.1038/s41416-020-1004-6

McGahan W; Waterhouse MA; O'Connell DL; Merrett ND; Goldstein D; Wyld D; Burmeister EA; Jordan SJ; Neale RE, 2020, 'Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis', Pancreatology, 20, pp. 1458 - 1464, http://dx.doi.org/10.1016/j.pan.2020.07.405

Pang TCY; Xu Z; Mekapogu AR; Pothula S; Becker TM; Goldstein D; Pirola RC; Wilson JS; Apte MV, 2020, 'An orthotopic resectional mouse model of pancreatic cancer', Journal of Visualized Experiments, 2020, pp. 1 - 13, http://dx.doi.org/10.3791/61726

Lees JG; White D; Keating BA; Barkl-Luke ME; Makker PGS; Goldstein D; Moalem-Taylor G, 2020, 'Oxaliplatin-induced haematological toxicity and splenomegaly in mice', PLoS ONE, 15, http://dx.doi.org/10.1371/journal.pone.0238164

Timmins HC; Li T; Kiernan MC; Baron-Hay S; Marx G; Boyle F; Goldstein D; Park SB, 2020, 'Taxane-induced peripheral neuropathy: differences in patient report and objective assessment', Supportive Care in Cancer, 28, pp. 4459 - 4466, http://dx.doi.org/10.1007/s00520-020-05299-y

Li T; Timmins HC; King T; Kiernan MC; Goldstein D; Park SB, 2020, 'Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials', Hematological Oncology, 38, pp. 229 - 243, http://dx.doi.org/10.1002/hon.2706

Timmins HC; Li T; Huynh W; Kiernan MC; Baron-Hay S; Boyle F; Goldstein D; Park SB, 2020, 'Electrophysiological and phenotypic profiles of taxane-induced neuropathy', Clinical Neurophysiology, 131, pp. 1979 - 1985, http://dx.doi.org/10.1016/j.clinph.2020.02.028

Tran B; Vajdic CM; Webber K; Laaksonen MA; Stavrou EP; Tiller K; Suchy S; Bosco AM; Harris MF; Lloyd AR; Goldstein D, 2020, 'Self-reported health, lifestyle and social circumstances of Australian adult cancer survivors: A propensity score weighted cross-sectional study', Cancer Epidemiology, 67, http://dx.doi.org/10.1016/j.canep.2020.101773

Makker PGS; White D; Lees JG; Parmar J; Goldstein D; Park SB; Howells J; Moalem-Taylor G, 2020, 'Acute changes in nerve excitability following oxaliplatin treatment in mice', Journal of Neurophysiology, 124, pp. 232 - 244, http://dx.doi.org/10.1152/jn.00260.2020

Goldstein D; Von Hoff DD; Chiorean EG; Reni M; Tabernero J; Ramanathan RK; Botteman M; Aly A; Margunato-Debay S; Lu B; Louis CU; McGovern D; Lee CK, 2020, 'Nomogram for Estimating Overall Survival in Patients with Metastatic Pancreatic Cancer', Pancreas, 49, pp. 744 - 750, http://dx.doi.org/10.1097/MPA.0000000000001563

Barbour AP; Samra JS; Haghighi KS; Donoghoe MW; Burge M; Harris MT; Chua YJ; Mitchell J; O’Rourke N; Chan H; Gebski VJ; Gananadha S; Croagh DG; Kench JG; Goldstein D; Barbour A; Samra JS; Harris M; Chua YJ; Yip S; Simes J; Hicks R; Coates A; Gurney H; Do V; Marschner I; Donoghoe M; Goldstone S; Yip S; Pavlakis N; Aghmesheh M; Joubert W; Grimes D; Harris M; Burge M; Bagia S; Jaber M; Gananadha S; Bryant R; Nathanson L; Cavallucci D; Barbour A; Fawcett J; O’Rourke T; Croagh D; Jones R, 2020, 'The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer', Annals of Surgical Oncology, 27, pp. 2506 - 2515, http://dx.doi.org/10.1245/s10434-020-08205-2

Chiang JCB; Zahari I; Markoulli M; Krishnan AV; Park SB; Semmler A; Goldstein D; Edwards K, 2020, 'The impact of anticancer drugs on the ocular surface', Ocular Surface, 18, pp. 403 - 417, http://dx.doi.org/10.1016/j.jtos.2020.03.008

Lim BT; Butow P; Sze ML; Girgis A; Jefford M; Goldstein D; Costa D, 2020, 'Impact of migrancy on cancer clinical trial participation: Factors associated with approach and consent in Australian-born versus migrant groups', Asia-Pacific Journal of Clinical Oncology, 16, pp. 115 - 122, http://dx.doi.org/10.1111/ajco.13290

Gronchi A; Bonvalot S; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom HJ; Van Coevorden F; Penel N; Kopp HG; Duffaud F; Goldstein D; Broto JM; Wardelmann E; Marréaud S; Smithers M; Le Cesne A; Zaffaroni F; Litière S; Blay JY; Casali PG, 2020, 'Quality of surgery and outcome in localized gastrointestinal stromal tumors treated within an international intergroup randomized clinical trial of adjuvant imatinib', JAMA Surgery, 155, http://dx.doi.org/10.1001/jamasurg.2020.0397

Reni M; Riess H; O'Reilly EM; Reeves JA; Chiorean E; George TJ; Scheithauer W; Pascal A; Lerch M; Brenner WS; Ko Y-J; Tabernero J; Van Cutsem E; Philip PA; Goldstein D; Berlin J; Biankin A; Tempero MA, 2020, 'Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.', Journal of Clinical Oncology, 38, pp. 4618 - 4618, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.4618

Battaglini E; Goldstein D; Park S, 2020, 'Determining the impact of chemotherapy-induced peripheral neuropathy: A survey of cancer survivors.', Journal of Clinical Oncology, 38, pp. e24080 - e24080, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e24080

Butow P; Davies G; Napier C; Thomas DM; Bartley N; Goldstein D; Ballinger ML; Juraskova I; Schlub TE; Tucker K; Meiser B; Young M-A, 2020, 'Return of results after somatic tumor mutation profiling in advanced cancer: Psychological impacts.', Journal of Clinical Oncology, 38, pp. 1541 - 1541, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1541

Butow P; Butow P; Davies G; Napier CE; Schlub T; Best MC; Bartley N; Juraskova I; Meiser B; Ballinger ML; Biesecker B; Goldstein D; Thomas DM, 2020, 'Assessment of the Value of Tumor Variation Profiling Perceived by Patients with Cancer', JAMA Network Open, 3, pp. e204721, http://dx.doi.org/10.1001/jamanetworkopen.2020.4721

Back to profile page